Fluticasone propionate
Identification
- Name
- Fluticasone propionate
- Accession Number
- DB00588
- Description
Fluticasone propionate is a synthetic glucocorticoid9,10Label. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications9,10Label. Fluticasone propionate was first approved in 19907.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Fluticasone propionate (DB00588)
- Weight
- Average: 500.571
Monoisotopic: 500.184429407 - Chemical Formula
- C25H31F3O5S
- Synonyms
- Fluticasone propionate
- External IDs
- CCI 18781
- CCI-18781
- PF-00241939
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisLabelas well as inflammatory and pruritic dermatoses9. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis8,10.
- Associated Conditions
- Allergic Rhinitis (AR)
- Allergy to Mold
- Allergy; Dander
- Asthma
- Bacterial Sinusitis
- Chronic Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Rhinosinusitis
- Emphysema
- House Dust Mite Allergy
- House dust allergy
- Itching of the nose
- Nasal Congestion
- Nonallergic Rhinitis
- Oesophagitis, Eosinophilic
- Perennial Rhinitis
- Pollen Allergy
- Rhinitis
- Rhinorrhoea
- Seasonal Allergic Rhinitis
- Skin Inflammation
- Sneezing
- Moderate, severe Perennial Allergic Rhinitis (PAR)
- Moderate, severe Seasonal Allergic Rhinitis
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats10Label. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin9,3.
- Mechanism of action
Fluticasone propionate works through an unknown mechanism to affect the action of various cell types and mediators of inflammation10. Fluticasone propionate activates glucocorticoid receptors and inhibits lung eosinophilia in rats10,9.
Target Actions Organism AGlucocorticoid receptor agonistHumans UProgesterone receptor agonistHumans UCytosolic phospholipase A2 inhibitorHumans UMineralocorticoid receptor antagonistHumans - Absorption
Intranasal bioavailability of fluticasone propionate is <2%, and oral bioavailability is <1%10Label. Intranasal exposure results in the majority of the dose being swallowed3. Topical absorption of fluticasone propionate is very low but can change depending on a number of factors including integrity of the skin and the presence of inflammation or disease9. A study of 24 healthy Caucasian males showed an inhaled bioavailability of 9.0%1.
- Volume of distribution
The volume of distribution of intravenous fluticasone propionate is 4.2L/kg10Label. A study of 24 healthy Caucasian males showed a volume of distribution at steady state of 577L following intravenous administration1.
- Protein binding
Fluticasone propionate is 99% protein bound in serum10. Topical fluticasone propionate is only 91% protein bound in serum however9.
- Metabolism
Fluticasone propionate is cleared from hepatic metabolism by cytochrome P450 3A410,4Label. Fluticasone propionate is hydrolysed at the FIVE-S-fluoromethyl carbothioate group, forming an inactive metabolite9,3Label.
Hover over products below to view reaction partners
- Route of elimination
Fluticasone propionate is mainly eliminated in the feces with <5% eliminated in the urine10,5Label.
- Half-life
7.8 hours for intravenous fluticasone propionate10Label. A study of 24 healthy Caucasian males shows a half life of 14.0 hours following intravenous administration and 10.8 hours following inhalation1.
- Clearance
1093mL/min for fluticasone propionate10. A study of 24 healthy Caucasian males showed a clearance of 63.9L/h following intravenous administration1.
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Fluticasone propionate's use in specific populations has not been well studied10. Fluticasone propionate is not carcinogenic, mutagenic, or clastogenic, nor did it affect fertility in animal studies10Label. Subcutaneous fluticasone propionate has been shown to produce teratogenic effects in rats though oral administration does not9Label. Generally, there are no reported adverse effects with fluticasone in pregnancy6. Fluticasone propionate in human milk may cause growth suppression, effects on endogenous corticosteroid production, or other effects9,2. Pediatric patients treated with fluticasone propionate ointment experienced adrenal suppression9. Geriatric patients treated with fluticasone propionate did not show any difference in safety or efficacy compared to other patient groups, though older patients may be more sensitive to adverse effects9. There is no difference in the clearance of fluticasone propionate across genders or raceLabel. Patients with hepatic impairment should be closely monitored due to the elimination mechanismLabel5.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Fluticasone propionate can be increased when it is combined with Abametapir. Abatacept The metabolism of Fluticasone propionate can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Fluticasone propionate. Acalabrutinib The metabolism of Fluticasone propionate can be decreased when combined with Acalabrutinib. Acarbose The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Acarbose. Aceclofenac The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Acemetacin. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Fluticasone propionate. Acetazolamide The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Acetazolamide. Acetohexamide The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Acetohexamide. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- No interactions found.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- International/Other Brands
- Ezicas (Intas) / Flixonase (GlaxoSmithKline) / Flixotide (GlaxoSmithKline) / FLOVENTHFA / Flunase (GlaxoSmithKline) / Nasofan (Teva) / Pirinase (GlaxoSmithKline) / Seretide (GlaxoSmithKline)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Aermony Respiclick Powder, metered Respiratory (inhalation) TEVA Canada Limited 2020-09-30 Not applicable Canada 
Aermony Respiclick Powder, metered Respiratory (inhalation) TEVA Canada Limited 2020-09-30 Not applicable Canada Aermony Respiclick Powder, metered Respiratory (inhalation) TEVA Canada Limited 2020-09-30 Not applicable Canada ArmonAir Digihaler Powder, metered 113 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US 
ArmonAir Digihaler Powder, metered 113 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US ArmonAir Digihaler Powder, metered 55 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US ArmonAir Digihaler Powder, metered 55 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US ArmonAir Digihaler Powder, metered 232 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US ArmonAir Digihaler Powder, metered 232 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2020-09-15 Not applicable US ArmonAir RespiClick Powder, metered 113 ug/1 Respiratory (inhalation) Teva Respiratory, LLC 2017-08-07 2019-03-31 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-fluticasone Spray, metered Nasal Apotex Corporation 2007-07-05 Not applicable Canada Apo-fluticasone HFA Aerosol, metered Respiratory (inhalation) Apotex Corporation Not applicable Not applicable Canada Beser Kit 0.5 mg/1mL Topical Medimetriks Pharmaceuticals, Inc 2019-04-01 Not applicable US Beser Lotion 0.5 mg/1mL Topical Medimetriks Pharmaceuticals, Inc. 2019-04-01 Not applicable US Fluticasone Spray, metered 50 ug/1 Nasal Direct Rx 2019-02-22 Not applicable US Fluticasone Spray, metered 50 ug/1 Nasal Unit Dose Services 2012-01-09 2016-07-06 US Fluticasone Cream 0.5 mg/1g Topical Sandoz 2004-05-14 2011-05-12 US Fluticasone Spray, metered 50 ug/1 Nasal Morton Grove Pharmaceuticals, Inc. 2012-01-09 Not applicable US Fluticasone Spray, metered 50 ug/1 Nasal Lake Erie Medical DBA Quality Care Products LLC 2018-09-07 Not applicable US Fluticasone Spray, metered 50 ug/1 Nasal Direct Rx 2014-01-01 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 24 Hour Allergy Nasal Spray, metered 50 ug/1 Nasal Shopko Stores Operating Co., LLC 2016-08-23 Not applicable US 24 Hour Allergy Nasal Spray, metered 50 ug/1 Nasal Walgreen Company 2016-05-27 Not applicable US 24 Hour Allergy Nasal Spray, metered 50 ug/1 Nasal HYVEE INC 2016-08-08 2019-05-01 US 24 Hour Allergy Relief nasal Spray, metered 50 ug/1 Nasal Kroger Company 2016-05-27 Not applicable US 24 Hour Allergy Relief Nasal Spray, metered 50 ug/1 Nasal Meijer Distribution Inc 2016-11-17 Not applicable US 24hr Nasal Allergy Relief Spray, metered Nasal Apotex Corporation 2017-07-19 Not applicable Canada Allergy Nasal Spray, metered 50 ug/1 Nasal Walgreen Company 2016-07-12 Not applicable US Allergy Nasal Spray, metered 50 ug/1 Nasal Rite Aid Corporation 2020-11-19 Not applicable US Allergy Relief Spray, metered 50 ug/1 Nasal Topco Associates LLC 2018-04-18 Not applicable US Allergy Relief Spray, metered 50 ug/1 Nasal Meijer Distribution Inc 2016-05-27 2018-09-01 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ACTIONFLU® 100/50 MCG Fluticasone propionate (100 mcg) + Salmeterol xinafoate (50 mcg) Powder Respiratory (inhalation) 2015-02-25 Not applicable Colombia 
ACTIONFLU® 250/50 MCG Fluticasone propionate (250 mcg) + Salmeterol xinafoate (50 mcg) Powder Respiratory (inhalation) 2015-02-25 Not applicable Colombia ACTIONFLU® 500/50 MCG Fluticasone propionate (500 mcg) + Salmeterol xinafoate (50 mcg) Powder Respiratory (inhalation) 2015-02-21 Not applicable Colombia Advair 100 Diskus Fluticasone propionate (100 mcg) + Salmeterol (50 mcg) Powder Respiratory (inhalation) Glaxosmithkline Inc 1999-09-24 Not applicable Canada Advair 125 Fluticasone propionate (125 mcg) + Salmeterol (25 mcg) Aerosol, metered Respiratory (inhalation) Glaxosmithkline Inc 2001-12-21 Not applicable Canada Advair 250 Fluticasone propionate (250 mcg) + Salmeterol (25 mcg) Aerosol, metered Respiratory (inhalation) Glaxosmithkline Inc 2001-12-21 Not applicable Canada Advair 250 Diskus Fluticasone propionate (250 mcg) + Salmeterol (50 mcg) Powder Respiratory (inhalation) Glaxosmithkline Inc 1999-09-24 Not applicable Canada Advair 500 Diskus Fluticasone propionate (500 mcg) + Salmeterol (50 mcg) Powder Respiratory (inhalation) Glaxosmithkline Inc 1999-09-24 Not applicable Canada Advair Diskus Fluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1) Powder Respiratory (inhalation) Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc 2012-02-17 2016-12-31 US Advair Diskus Fluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1) Powder Respiratory (inhalation) Aidarex Pharmaceuticals LLC 2001-02-28 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cenovia Fluticasone propionate (0.025 g/0.025g) + Hydroquinone (2 g/2g) + Tretinoin (0.025 g/0.025g) Kit Topical Accumix Pharmaceuticals 2014-12-15 2015-07-17 US Fluticasone Propionate 0.05% / Niacinamide 4% Fluticasone propionate (0.05 g/100g) + Nicotinamide (4 g/100g) Cream Topical Sincerus Florida, LLC 2019-05-14 Not applicable US Ticanase Fluticasone propionate (50 ug/1) Kit Nasal PureTek Corporation 2016-01-11 Not applicable US Validerm Fluticasone propionate (0.05 g/0.05g) + Calcitriol (0.2 mg/0.2mg) + Tacrolimus hydrate (0.05 g/0.05g) Kit Topical Accumix Pharmaceuticals 2014-12-15 2015-07-17 US
Categories
- Drug Categories
- Adrenal Cortex Hormones
- Adrenals
- Agents to Treat Airway Disease
- Androstadienes
- Androstanes
- Androstenes
- Anti-Allergic Agents
- Anti-Asthmatic Agents
- Anti-Inflammatory Agents
- Autonomic Agents
- Bronchodilator Agents
- Central Nervous System Depressants
- Corticosteroids
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Potent (Group III)
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 CYP2C8 Inhibitors (strong)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Dermatologicals
- Immunosuppressive Agents
- OATP1B1/SLCO1B1 Inhibitors
- P-glycoprotein substrates
- Peripheral Nervous System Agents
- Respiratory System Agents
- Steroids
- Thyroxine-binding globulin inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Steroid esters
- Direct Parent
- Steroid esters
- Alternative Parents
- Androgens and derivatives / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Thioesters / Secondary alcohols / Carbothioic S-esters / Carboxylic acid esters / Cyclic alcohols and derivatives show 8 more
- Substituents
- 11-beta-hydroxysteroid / 11-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 6-halo-steroid / 9-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl fluoride / Alkyl halide show 28 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- thioester, propanoate ester, 11beta-hydroxy steroid, steroid ester, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid (CHEBI:31441)
Chemical Identifiers
- UNII
- O2GMZ0LF5W
- CAS number
- 80474-14-2
- InChI Key
- WMWTYOKRWGGJOA-CENSZEJFSA-N
- InChI
- InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
- IUPAC Name
- (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
- SMILES
- [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
References
- Synthesis Reference
Joseph Kaspi, Oded Arad, Michael Brand, Moty Shookrun, Simona Malka, Mohammed Alnabari, Shalom Hazan, Vlado Malesevic, "Synthesis and powder preparation of fluticasone propionate." U.S. Patent US20060009435, issued January 12, 2006.
US20060009435- General References
- Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x. [PubMed:23184737]
- Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5. [PubMed:23578031]
- Phillipps GH: Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:19-23. [PubMed:2287791]
- Harding SM: The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:25-9. [PubMed:2287792]
- Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54. [PubMed:11589253]
- Choi JS, Han JY, Kim MY, Velazquez-Armenta EY, Nava-Ocampo AA: Pregnancy outcomes in women using inhaled fluticasone during pregnancy: a case series. Allergol Immunopathol (Madr). 2007 Nov-Dec;35(6):239-42. [PubMed:18047814]
- FDA Approved Drug Products December 1990 [Link]
- FDA Approved Drugs: Dymista nasal spray [Link]
- Fluticasone Propionate (Cutivate) Ointment FDA Label [File]
- Fluticasone Propionate (Flonase) Nasal Spray FDA Label [File]
- External Links
- Human Metabolome Database
- HMDB0005036
- KEGG Drug
- D01708
- PubChem Compound
- 444036
- PubChem Substance
- 46506140
- ChemSpider
- 392059
- BindingDB
- 50354849
- 50121
- ChEBI
- 31441
- ChEMBL
- CHEMBL1473
- ZINC
- ZINC000003920027
- Therapeutic Targets Database
- DAP001039
- PharmGKB
- PA449686
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Fluticasone_propionate
- AHFS Codes
- 68:04.00 — Adrenals
- 52:08.00 — Anti-inflammatory Agents
- 84:06.00 — Anti-inflammatory Agents
- 52:08.08 — Corticosteroids
- FDA label
- Download (651 KB)
- MSDS
- Download (53.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Basic Science Healthy Volunteers 1 4 Completed Not Available Asthma 1 4 Completed Basic Science Asthma 1 4 Completed Basic Science Chronic Obstructive Pulmonary Disease (COPD) 2 4 Completed Basic Science Mild Intermittent Asthma 1 4 Completed Diagnostic Asthma 1 4 Completed Diagnostic Asthmatic Smokers / Non-asthmatic Smokers 1 4 Completed Other Asthma 1 4 Completed Other Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Other Ocular Hypertension / Open-angle Glaucoma (OAG) 1
Pharmacoeconomics
- Manufacturers
- Glaxosmithkline
- Glaxo group ltd dba glaxosmithkline
- Altana inc
- G and w laboratories inc
- Kv pharmaceutical co
- Perrigo new york inc
- Tolmar inc
- Nycomed us inc
- Taro pharmaceutical industries ltd
- Apotex inc richmond hill
- Hi tech pharmacal co inc
- Roxane laboratories inc
- Packagers
- Apotex Inc.
- A-S Medication Solutions LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- E. Fougera and Co.
- G & W Labs
- GlaxoSmithKline Inc.
- Hi Tech Pharmacal Co. Inc.
- Letco Medical Inc.
- Nycomed Inc.
- Palmetto Pharmaceuticals Inc.
- Penn Labs
- Perrigo Co.
- Pharmaderm
- Physicians Total Care Inc.
- Professional Co.
- Promex Medical Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Roxane Labs
- Sandoz
- Stat Scripts LLC
- Taro Pharmaceuticals USA
- Tolmar Inc.
- Dosage Forms
Form Route Strength Spray, metered Nasal Aerosol; suspension Respiratory (inhalation) Powder Oral; Respiratory (inhalation) Powder Respiratory (inhalation) Aerosol, metered Respiratory (inhalation) Powder, metered Respiratory (inhalation) Powder Respiratory (inhalation) 100 mcg Powder Respiratory (inhalation) 250 mcg Powder Respiratory (inhalation) 50 mcg Powder Respiratory (inhalation) 500 mcg Aerosol Respiratory (inhalation) 25 mcg Gas Respiratory (inhalation) Aerosol, powder Respiratory (inhalation) Aerosol, metered Respiratory (inhalation) 25 mcg Aerosol; suspension Respiratory (inhalation) 25 mcg Aerosol; suspension Respiratory (inhalation) 50 mcg Suspension Intrasinal; Nasal Powder, metered Respiratory (inhalation) 113 ug/1 Powder, metered Respiratory (inhalation) 232 ug/1 Powder, metered Respiratory (inhalation) 55 ug/1 Kit Topical 0.5 mg/1mL Lotion Topical 0.5 mg/1mL Cream Topical 0.05 % Spray Nasal 50 mcg/100mg Spray, metered Nasal Spray, suspension Respiratory (inhalation) Spray, suspension Nasal 137 mcg Capsule Respiratory (inhalation) 12 mcg Suspension Intrasinal; Nasal Suspension Respiratory (inhalation) 0.5 mg/2ml Suspension Respiratory (inhalation) 2 mg/2ml Solution Respiratory (inhalation) 125 mcg Solution Respiratory (inhalation) 250 mcg Solution Respiratory (inhalation) 50 mcg Spray Nasal 50 µg Spray Nasal Solution / drops Nasal 400 mcg Aerosol, metered Respiratory (inhalation) 125 mcg Aerosol, metered Respiratory (inhalation) 50 mg Aerosol Respiratory (inhalation) Spray, metered Respiratory (inhalation) Suspension Respiratory (inhalation) Aerosol, metered; suspension Nasal Spray, metered Nasal 50 mcg Aerosol, metered Respiratory (inhalation) 110 ug/1 Aerosol, metered Respiratory (inhalation) 220 ug/1 Aerosol, metered Respiratory (inhalation) 44 ug/1 Powder Respiratory (inhalation) 100 ug/1 Powder Respiratory (inhalation) 250 ug/1 Powder Respiratory (inhalation) 50 ug/1 Powder, metered Respiratory (inhalation) 100 ug/1 Powder, metered Respiratory (inhalation) 250 ug/1 Powder, metered Respiratory (inhalation) 50 ug/1 Aerosol, metered Respiratory (inhalation) Suspension Buccal; Respiratory (inhalation) Solution Oral; Respiratory (inhalation) Solution Respiratory (inhalation) Cream Topical Aerosol; suspension Respiratory (inhalation) Spray Nasal 50 mcg Capsule Respiratory (inhalation) Aerosol; aerosol, metered Respiratory (inhalation) Gas Respiratory (inhalation) Cream Topical 0.5 mg/1g Cream Topical 0.5 mg/1 Ointment Topical 0.05 mg/1g Spray, metered Nasal 50 ug/1 Spray, metered Nasal 50 ug/0.1g Cream Topical Powder, metered Respiratory (inhalation) Aerosol, spray Respiratory (inhalation) Suspension Oral; Respiratory (inhalation) Aerosol Buccal Aerosol; suspension Respiratory (inhalation) 125 mcg Aerosol; suspension Respiratory (inhalation) 250 mcg Suspension Nasal; Respiratory (inhalation) Solution Intrasinal; Nasal Capsule Respiratory (inhalation) 50 mcg Powder Respiratory (inhalation) Suspension Respiratory (inhalation) 25 mcg Powder Respiratory (inhalation) 10.9 mcg Powder Respiratory (inhalation) 25 mcg Suspension Respiratory (inhalation) Spray Nasal Kit Nasal 50 ug/1 Spray Nasal 50 ug/1 Powder Respiratory (inhalation) 9 mcg Kit Topical Aerosol, metered Respiratory (inhalation) 250 mcg Aerosol, metered Respiratory (inhalation) 50 mcg Spray, metered Nasal 93 ug/1 Spray, suspension Nasal Aerosol Respiratory (inhalation) Spray, suspension Nasal - Prices
Unit description Cost Unit Fluticasone propionate powder 1500.0USD g Cutivate 0.05% Lotion 120ml Bottle 454.6USD bottle Advair Diskus 60 500-50 mcg/dose Aerosol Disp Pack 328.14USD disp Advair Diskus 60 250-50 mcg/dose Aerosol Disp Pack 249.48USD disp Flovent HFA 220 mcg/act Aerosol 12 gm Inhaler 237.67USD inhaler Cutivate 0.05% Cream 60 gm Tube 217.11USD tube Advair Diskus 60 100-50 mcg/dose Aerosol Disp Pack 200.79USD disp Advair Diskus 14 500-50 mcg/dose Aerosol Disp Pack 156.64USD disp Flovent HFA 110 mcg/act Aerosol 12 gm Inhaler 153.01USD inhaler Cutivate 0.005% Ointment 60 gm Tube 128.28USD tube Flovent HFA 44 mcg/act Aerosol 10.6 gm Inhaler 114.27USD inhaler Flovent Diskus 60 50 mcg/blist Aerosol Inhaler 104.74USD inhaler Flonase 50 mcg/act Suspension 16 gm Bottle 94.59USD bottle Fluticasone Propionate 50 mcg/act Suspension 16 gm Bottle 78.28USD bottle Cutivate 0.05% Cream 30 gm Tube 62.99USD tube Fluticasone Propionate 0.005% Ointment 60 gm Tube 56.27USD tube Fluticasone Propionate 0.05% Cream 60 gm Tube 56.27USD tube Cutivate 0.005% Ointment 30 gm Tube 44.99USD tube Fluticasone Propionate 0.005% Ointment 30 gm Tube 35.67USD tube Fluticasone Propionate 0.05% Cream 30 gm Tube 35.67USD tube Cutivate 0.005% Ointment 15 gm Tube 32.99USD tube Cutivate 0.05% Cream 15 gm Tube 32.99USD tube Advair hfa 230-21 mcg inhaler 25.04USD g Fluticasone Propionate 0.005% Ointment 15 gm Tube 23.14USD tube Fluticasone Propionate 0.05% Cream 15 gm Tube 23.14USD tube Advair hfa 115-21 mcg inhaler 18.13USD g Flovent hfa 220 mcg inhaler 15.54USD g Advair hfa 45-21 mcg inhaler 14.59USD g Flovent hfa 110 mcg inhaler 12.26USD g Flovent hfa 44 mcg inhaler 10.99USD g Flonase 0.05% nasal spray 5.68USD g Advair 500-50 diskus 5.26USD each Advair 250-50 diskus 4.0USD each Cutivate 0.05% cream 3.48USD g Advair 100-50 diskus 3.22USD each Flovent 250 mcg diskus 2.45USD each Flovent 100 mcg diskus 1.83USD each Flovent 50 mcg diskus 1.74USD each Flovent Diskus 500 mcg/dose Metered Inhalation Powder 1.55USD dose Flovent Diskus 250 mcg/dose Metered Inhalation Powder 0.77USD dose Flovent Hfa 250 mcg/dose Metered Dose Aerosol 0.77USD dose Flovent Hfa 125 mcg/dose Metered Dose Aerosol 0.39USD dose Flovent Hfa 50 mcg/dose Metered Dose Aerosol 0.22USD dose DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region USRE40045 No 2008-02-05 2010-09-07 US CA2317999 No 2004-11-09 2020-09-11 Canada CA2125667 No 2000-03-13 2012-12-04 Canada US5873360 Yes 1999-02-23 2016-08-23 US US6446627 No 2002-09-10 2017-12-18 US US6743413 Yes 2004-06-01 2021-12-01 US US6938796 Yes 2005-09-06 2018-07-16 US US6997349 Yes 2006-02-14 2018-07-16 US US6431168 Yes 2002-08-13 2018-12-08 US US7107986 Yes 2006-09-19 2018-12-06 US US7500444 Yes 2009-03-10 2026-08-26 US US6315173 Yes 2001-11-13 2018-06-23 US US7143908 Yes 2006-12-05 2018-07-16 US US6170717 Yes 2001-01-09 2018-06-23 US US7350676 Yes 2008-04-01 2019-02-24 US US7832351 Yes 2010-11-16 2023-12-19 US US6161724 Yes 2000-12-19 2018-07-16 US US6510969 Yes 2003-01-28 2018-06-23 US US6966467 Yes 2005-11-22 2018-06-23 US US6435372 Yes 2002-08-20 2018-07-16 US US7300669 No 2007-11-27 2019-10-20 US US8163723 Yes 2012-04-24 2024-02-29 US US9259428 Yes 2016-02-16 2023-12-13 US US8168620 Yes 2012-05-01 2026-08-24 US US6871646 No 2005-03-29 2021-06-23 US US8978966 No 2015-03-17 2032-01-13 US US6701917 No 2004-03-09 2021-06-23 US US7540282 No 2009-06-02 2023-05-06 US US6748947 No 2004-06-15 2021-06-23 US US8006690 No 2011-08-30 2021-06-23 US US6718972 No 2004-04-13 2021-06-23 US US9216260 No 2015-12-22 2031-06-28 US US8651103 No 2014-02-18 2028-03-26 US US8327844 No 2012-12-11 2023-10-03 US US7975690 No 2011-07-12 2025-08-18 US US6715485 No 2004-04-06 2020-03-03 US US8550073 No 2013-10-08 2029-10-22 US US8978647 No 2015-03-17 2030-12-06 US US9463288 No 2016-10-11 2025-05-19 US US8714149 No 2014-05-06 2032-02-25 US US9616024 No 2017-04-11 2024-09-01 US US9066957 No 2015-06-30 2034-10-06 US US9415008 No 2016-08-16 2034-10-06 US US9731087 No 2017-08-15 2031-05-18 US US9072857 No 2015-07-07 2021-04-10 US US9468727 No 2016-10-18 2020-07-30 US US8522778 No 2013-09-03 2022-05-11 US US8555878 No 2013-10-15 2020-03-20 US US9901585 No 2018-02-27 2023-06-13 US US9861771 No 2018-01-09 2020-10-11 US US9987229 No 2018-06-05 2024-09-01 US US10022510 No 2018-07-17 2031-05-18 US US10076615 No 2018-09-18 2029-07-30 US US10076614 No 2018-09-18 2034-10-20 US US10124132 No 2018-11-13 2027-03-06 US US10124131 No 2018-11-13 2031-05-18 US US9782550 No 2017-10-10 2035-08-28 US US9782551 No 2017-10-10 2035-08-28 US US10179216 No 2019-01-15 2033-07-08 US US10195375 No 2019-02-05 2031-02-14 US US10252010 No 2019-04-09 2031-02-07 US US10300229 No 2019-05-28 2035-07-07 US US10478574 No 2019-11-19 2033-11-04 US US10569034 No 2016-08-16 2036-08-16 US US10561808 No 2012-01-01 2032-01-01 US US10765820 No 2005-05-19 2025-05-19 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 261-273 °C [MSDS] water solubility Insoluble [MSDS] logP 2.78 [MSDS] - Predicted Properties
Property Value Source Water Solubility 0.0114 mg/mL ALOGPS logP 3.69 ALOGPS logP 3.72 ChemAxon logS -4.6 ALOGPS pKa (Strongest Acidic) 13.56 ChemAxon pKa (Strongest Basic) -3.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 80.67 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 121.65 m3·mol-1 ChemAxon Polarizability 49.26 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9964 Blood Brain Barrier + 0.9701 Caco-2 permeable + 0.5417 P-glycoprotein substrate Substrate 0.7099 P-glycoprotein inhibitor I Inhibitor 0.7192 P-glycoprotein inhibitor II Non-inhibitor 0.8636 Renal organic cation transporter Non-inhibitor 0.8689 CYP450 2C9 substrate Non-substrate 0.868 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Substrate 0.7407 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Inhibitor 0.8988 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8682 Ames test Non AMES toxic 0.798 Carcinogenicity Non-carcinogens 0.8901 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.3753 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.99 hERG inhibition (predictor II) Non-inhibitor 0.6125
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-03dl-0497100000-b64248896abdef386eaf
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Andersson O, Cassel TN, Gronneberg R, Bronnegard M, Stierna P, Nord M: In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma. J Allergy Clin Immunol. 1999 Apr;103(4):595-600. [PubMed:10200007]
- Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
- Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731]
- Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597-602. [PubMed:7878687]
- Johnson M: Fluticasone propionate: safety profile. Cutis. 1996 Feb;57(2 Suppl):10-2. [PubMed:8646863]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
- Gene Name
- PGR
- Uniprot ID
- P06401
- Uniprot Name
- Progesterone receptor
- Molecular Weight
- 98979.96 Da
References
- Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
- Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Phospholipase a2 activity
- Specific Function
- Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
- Gene Name
- PLA2G4A
- Uniprot ID
- P47712
- Uniprot Name
- Cytosolic phospholipase A2
- Molecular Weight
- 85238.2 Da
References
- Sano A, Munoz NM, Sano H, Choi J, Zhu X, Jacobs B, Leff AR: Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med. 1999 Jun;159(6):1903-9. [PubMed:10351938]
- Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E, Lambertino AT, Xu C, Munoz NM, Leff AR: Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J. 2004 Apr;23(4):511-7. [PubMed:15083746]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
- Gene Name
- NR3C2
- Uniprot ID
- P08235
- Uniprot Name
- Mineralocorticoid receptor
- Molecular Weight
- 107066.575 Da
References
- Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
- Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
- Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
- Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
- FDA reports [Link]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid binding
- Specific Function
- Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
- Gene Name
- SERPINA6
- Uniprot ID
- P08185
- Uniprot Name
- Corticosteroid-binding globulin
- Molecular Weight
- 45140.49 Da
References
- Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26. [PubMed:23300763]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- FDA reports [Link]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- FDA reports [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- FDA reports [Link]
Drug created on June 13, 2005 13:24 / Updated on March 08, 2021 22:25